ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes
Copenhagen, Denmark, September 14, 2006 -- Several abstracts presented today at the 42nd Annual Meeting of the European Association for the Study of Diabetes (EASD) indicated that ACTOS (pioglitazone HCl), an oral antidiabetic medication, demonstrated significant cardiovascular benefits such as reducing the risk of heart attack and/or stroke and acute coronary syndrome in patients with type 2 di...ACTOS (pioglitazone HCl) to be studied in new trial
Washington, DC, June 9, 2006 Researchers today at the American Diabetes Association (ADA) 66th Annual Scientific Sessions presented data showing the relationship between baseline characteristics and cardiac risk factors in patients enrolled in a new clinical trial called CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne). This is the largest and longest study to exam...ACTOplus met (pioglitazone HCl and metformin HCl)
LINCOLNSHIRE, Ill., November 1, 2005 Takeda Pharmaceuticals North America, Inc. today announced that ACTOplus met (ramelteon) on July 22, 2005.... ...ACTOplus met combines ACTOS® (pioglitazone HCl) and metformin, two widely used diabetes medications, in a single tablet. ACTOS directly targets insuli...ACTOS (pioglitazone HCl) significantly improved components of diabetic dyslipidemia
... ...Lincolnshire, IL, June 29, 2005 A new study published in today's issue of Diabetes Care demonstrated that ACTOS improved components of diabetic dyslipidemia to a significantly greater extent than Avandia. Specifically, the results indicated that treatment with ACTOS lowered triglycerides (a type of lipid, or fat, found in food and the body), increased HDL-C ("good" cholesterol), and im...Diabetes medication pioglitazone HCl may significantly improve predictors of cardiovascular risk
Mainz, Germany, May 9, 2005 Study results published in the May 17th issue of Circulation, the journal of the American Heart Association, found that the diabetes medication pioglitazone HCl reduced carotid artery intima-media thickness (IMT). Patients taking pioglitazone also experienced significant reductions in insulin resistance, C-reactive protein (a marker for inflammation) and blood pressu...